FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569270003> ?p ?o ?g. }

• W1569270003 endingPage "70" @default.
• W1569270003 startingPage "65" @default.
• W1569270003 abstract "Aims To evaluate the effect of steady-state carbamazepine administration on the steady-state pharmacokinetics of ziprasidone in healthy young adults, in an open, randomised, parallel-group study. Methods Twenty-five subjects were randomized to one of two treatment groups. Group 1 received 20 mg ziprasidone twice daily on days 1 and 2, and a single dose on day 3. A single 100 mg dose of carbamazepine was given once daily on days 5 and 6 and twice daily on days 7 and 8, followed by 200 mg twice daily until day 28 and on the morning only on day 29. Ziprasidone 20 mg was also administered twice daily on days 26 and 27 and in the morning only on day 28. Group 2 received the same treatment regimen with carbamazepine replaced by placebo. Pharmacokinetic data were obtained on days 3 and 28. Results Nine subjects in group 1 and 10 in group 2 completed all three treatment periods (ziprasidone, carbamazepine or placebo; and ziprasidone plus carbamazepine or placebo). Carbamazepine administration to group 1 was associated with modest reductions in ziprasidone exposure, with mean decreases in ziprasidone AUC(0,12 h) and Cmax values of 36% and 27%, respectively, on day 28 compared with day 3 (P<0.03). The mean differences between day 28 and day 3 ziprasidone AUC(0,12 h) and Cmax values were also statistically significantly greater in the carbamazepine group than in the placebo group. The mean half-life of ziprasidone decreased by 1 h from day 3 to day 28 in the subjects receiving carbamazepine, compared with virtually no change in the placebo group. All adverse events were mild or moderate in severity and there were no serious adverse events, or clinically significant changes in ECGs and vital signs throughout the study. Conclusions Induction of CYP3A4 with carbamazepine led to a modest reduction (<36%) in steady-state exposure to ziprasidone that is believed to be clinically insignificant." @default.
• W1569270003 created "2016-06-24" @default.
• W1569270003 creator A5011592597 @default.
• W1569270003 creator A5022672651 @default.
• W1569270003 creator A5049177702 @default.
• W1569270003 creator A5063048473 @default.
• W1569270003 creator A5086483980 @default.
• W1569270003 date "2000-01-01" @default.
• W1569270003 modified "2023-10-12" @default.
• W1569270003 title "The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers" @default.
• W1569270003 cites W13210705 @default.
• W1569270003 cites W1492127548 @default.
• W1569270003 cites W1563951236 @default.
• W1569270003 cites W1659296215 @default.
• W1569270003 cites W1739511219 @default.
• W1569270003 cites W1967803753 @default.
• W1569270003 cites W1993007848 @default.
• W1569270003 cites W1993044801 @default.
• W1569270003 cites W2001485493 @default.
• W1569270003 cites W2033336706 @default.
• W1569270003 cites W2049117121 @default.
• W1569270003 cites W2062094809 @default.
• W1569270003 cites W2076808235 @default.
• W1569270003 cites W2082523704 @default.
• W1569270003 cites W2087831413 @default.
• W1569270003 cites W2099448156 @default.
• W1569270003 cites W2111151510 @default.
• W1569270003 cites W2115745188 @default.
• W1569270003 cites W2133057678 @default.
• W1569270003 cites W2151724311 @default.
• W1569270003 cites W2396005913 @default.
• W1569270003 cites W4302610194 @default.
• W1569270003 cites W52611978 @default.
• W1569270003 doi "https://doi.org/10.1046/j.1365-2125.2000.00157.x" @default.
• W1569270003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2015057" @default.
• W1569270003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10771457" @default.
• W1569270003 hasPublicationYear "2000" @default.
• W1569270003 type Work @default.
• W1569270003 sameAs 1569270003 @default.
• W1569270003 citedByCount "74" @default.
• W1569270003 countsByYear W15692700032012 @default.
• W1569270003 countsByYear W15692700032013 @default.
• W1569270003 countsByYear W15692700032014 @default.
• W1569270003 countsByYear W15692700032016 @default.
• W1569270003 countsByYear W15692700032019 @default.
• W1569270003 countsByYear W15692700032020 @default.
• W1569270003 countsByYear W15692700032022 @default.
• W1569270003 countsByYear W15692700032023 @default.
• W1569270003 crossrefType "journal-article" @default.
• W1569270003 hasAuthorship W1569270003A5011592597 @default.
• W1569270003 hasAuthorship W1569270003A5022672651 @default.
• W1569270003 hasAuthorship W1569270003A5049177702 @default.
• W1569270003 hasAuthorship W1569270003A5063048473 @default.
• W1569270003 hasAuthorship W1569270003A5086483980 @default.
• W1569270003 hasBestOaLocation W15692700031 @default.
• W1569270003 hasConcept C112705442 @default.
• W1569270003 hasConcept C118552586 @default.
• W1569270003 hasConcept C126322002 @default.
• W1569270003 hasConcept C142724271 @default.
• W1569270003 hasConcept C19720800 @default.
• W1569270003 hasConcept C204787440 @default.
• W1569270003 hasConcept C22979827 @default.
• W1569270003 hasConcept C27081682 @default.
• W1569270003 hasConcept C2776412080 @default.
• W1569270003 hasConcept C2777270317 @default.
• W1569270003 hasConcept C2778186239 @default.
• W1569270003 hasConcept C2779253243 @default.
• W1569270003 hasConcept C2780494398 @default.
• W1569270003 hasConcept C42219234 @default.
• W1569270003 hasConcept C71924100 @default.
• W1569270003 hasConcept C98274493 @default.
• W1569270003 hasConceptScore W1569270003C112705442 @default.
• W1569270003 hasConceptScore W1569270003C118552586 @default.
• W1569270003 hasConceptScore W1569270003C126322002 @default.
• W1569270003 hasConceptScore W1569270003C142724271 @default.
• W1569270003 hasConceptScore W1569270003C19720800 @default.
• W1569270003 hasConceptScore W1569270003C204787440 @default.
• W1569270003 hasConceptScore W1569270003C22979827 @default.
• W1569270003 hasConceptScore W1569270003C27081682 @default.
• W1569270003 hasConceptScore W1569270003C2776412080 @default.
• W1569270003 hasConceptScore W1569270003C2777270317 @default.
• W1569270003 hasConceptScore W1569270003C2778186239 @default.
• W1569270003 hasConceptScore W1569270003C2779253243 @default.
• W1569270003 hasConceptScore W1569270003C2780494398 @default.
• W1569270003 hasConceptScore W1569270003C42219234 @default.
• W1569270003 hasConceptScore W1569270003C71924100 @default.
• W1569270003 hasConceptScore W1569270003C98274493 @default.
• W1569270003 hasIssue "S1" @default.
• W1569270003 hasLocation W15692700031 @default.
• W1569270003 hasLocation W15692700032 @default.
• W1569270003 hasLocation W15692700033 @default.
• W1569270003 hasLocation W15692700034 @default.
• W1569270003 hasOpenAccess W1569270003 @default.
• W1569270003 hasPrimaryLocation W15692700031 @default.
• W1569270003 hasRelatedWork W1978721469 @default.
• W1569270003 hasRelatedWork W1991965294 @default.
• W1569270003 hasRelatedWork W2348752634 @default.
• W1569270003 hasRelatedWork W2355979670 @default.

• next